Overview

A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
Phase:
Phase 1
Details
Lead Sponsor:
Human Genome Sciences Inc.